Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 4Stomach Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 2Squamous Cell Carcinoma of Head and Neck 1Esophageal Neoplasms 1

Interventions

Fluorouracil 7Oxaliplatin 6Nivolumab 5Leucovorin 5fludarabine 4Paclitaxel 4Docetaxel 4Cyclophosphamide 4Capecitabine 4zimberelimab 3pembrolizumab 3aldesleukin 3Trastuzumab 3Ramucirumab 3ulixertinib 2trastuzumab deruxtecan 2fludarabine phosphate 2Specimen Handling 2Irinotecan 2Cisplatin 2zolbetuximab 1zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1toripalimab 1tislelizumab 1sodium propionate 1sapanisertib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Stomach Neoplasms × Ramucirumab × 30 days × Clear all
NCT04632459 2026-06-05

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Samsung Medical Center

Phase 2 Completed
26 enrolled 9 charts
Gastrointestinal

Stomach Neoplasms

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Daiichi Sankyo

Phase 3 Active not recruiting
490 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT06251973 2026-05-15

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡